# A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.

> **NCT01929317** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 81 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Ropinirole CR 2mg tablet
- **DRUG:** Ropinirole CR 8mg tablet
- **DRUG:** Ropinirole CR matching Placebo tablet

## Key facts

- **NCT ID:** NCT01929317
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08-28
- **Primary completion:** 2014-09-16
- **Final completion:** 2015-06-09
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2018-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01929317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01929317, "A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01929317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*